Evidence map›Paper›PMID 35921223›Full record

ArticleHuman vaccines & immunotherapeutics2022

Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico.

Enrique Chacon-Cruz, Erika Zoe Lopatynsky-Reyes, Gloria Huerta-Garcia, Maria Yolanda Cervantes-Apolinar, Adriana Guzman-Holst, Desiree Van Oorschot

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. The economic burden of seasonal influenza - China, 2010-2019.Human vaccines & immunotherapeutics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Enrique Chacon-CruzPediatric Infectious Diseases Department, Hospital General de Tijuana, Tijuana, Mexico.ORCID 0000-0003-2466-4920
Erika Zoe Lopatynsky-ReyesSchool of Family Medicine and Public Health, University of California in San Diego, San Diego, CA, USA.ORCID 0000-0003-4121-6521
Gloria Huerta-GarciaGSK, Panama, Panama.ORCID 0000-0003-3867-4935
Maria Yolanda Cervantes-ApolinarGSK, Mexico City, Mexico.ORCID 0000-0002-4239-9588
Adriana Guzman-HolstGSK, Panama, Panama.ORCID 0000-0002-6753-2541
Desiree Van OorschotGSK, Wavre, Belgium.ORCID 0000-0002-0382-0333
GlaxoSmithKline (Belgium) · BEMSD (Mexico) · MXUniversidad de Tijuana · MXUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive meningococcal disease (IMD) is an uncommon but serious and potentially fatal condition mainly affecting children and adolescents. Active surveillance between 2005 and 2016 at Tijuana General Hospital, Mexico, indicated that the incidence of IMD in Tijuana was higher than previously thought, at 2.69 per 100,000 population aged <16 years. The objective of this study was to estimate the economic burden associated with 51 IMD cases in children aged <16 years identified over the 11 years of active surveillance at Tijuana General Hospital, Mexico. Healthcare resource usage for the IMD cases was obtained from the hospital database and combined with unit costs from the hospital purchasing department or national databases to estimate total healthcare costs over a follow-up period of 3 months. Societal costs were represented by the value of lost wages for parents or guardians. All costs were expressed in US$. Over the 11-year study period there were 51 IMD cases, of which 13 (25%) were fatal. The total cost for all 51 cases over the 11-year study period was US$1,054,499 (average per case US$20,676), of which direct healthcare costs comprised US$1,029,948 (average per case US$20,195) and societal costs US$24,551 (average per case US$481). Extrapolated to the population of Tijuana region aged <16 years, the estimated annual economic burden of IMD was US$268,794. The major cost driver was the cost of hospitalization. These data illustrate the significant economic burden associated with IMD in Tijuana, and will be useful in assessing optimal vaccination programs against meningococcal disease in Mexico.

Indexed as

Meningococcal InfectionsMeningococcal VaccinesAdolescentChildHealth Care CostsHospitalizationHumansIncidenceVaccinationMeningococcal VaccinesAdolescentschildreneconomic burdenmeningococcal diseaseMexico

Identifiers

PMID35921223
PMCPMC9746419
OpenAlexW4289637496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.